Whalesbook
OneSource Specialty Pharma's shares surged Friday after its partner, Orbicular Pharmaceutical Technologies, received tentative US FDA approval for a generic version of the blockbuster drug Ozempic. The stock climbed about 4% to ₹1,833.05, bucking a broader market decline. This rally extends a strong weekly trend, with OneSource gaining 22% while the benchmark Sensex dropped 2.5%. The tentative approval, granted on April 21, 2026, for an Abbreviated New Drug Application (ANDA) for Semaglutide Injection, signifies that the FDA has accepted the application, pending patent and exclusivity resolutions.
Despite the stock's strong recovery – up 73% from its 52-week low of ₹1,075 on January 30, 2026 – OneSource's recent financial performance shows challenges. For the first nine months of fiscal year 2026 (9MFY26), total operating income was ₹993 crore, down from ₹1,019 crore in the same period last year. Operating profit margins before interest, depreciation, and taxes (PBILDT) also compressed significantly to 21.37% from 27.87%. The company attributed this dip to delays in regulatory approvals for semaglutide affecting Canadian deliveries and a strategic decision to delay new manufacturing agreements to focus capacity on upcoming commercial supplies. In contrast, fiscal year 2025 saw robust revenue of ₹1,445 crore with a healthy 32% PBILDT margin, boosted by integrating acquired businesses.
The market for generic semaglutide is expected to see substantial growth, with projections suggesting it could reach nearly $8 billion by 2030, potentially cutting prices by up to 50%. While OneSource's partner has secured tentative approval, launching a generic drug often takes time. Typical development can span three to four years, with final FDA approval sometimes taking 18 months or more after initial review, especially if patent disputes arise. Ozempic's patents expire at different times globally, with US expirations anticipated around 2032. As of April 2026, no generic Ozempic has received final FDA approval in the US. Analysts remain cautiously optimistic, maintaining a consensus 'Buy' rating and an average 12-month price target of ₹1,943 to ₹1,985. OneSource Specialty Pharma, with a market capitalization of about ₹20,500 crore, has a high P/E ratio of around 700-800x, indicating strong growth expectations but also current earnings pressures.
The broader Indian Contract Development and Manufacturing Organization (CDMO) sector is forecast to grow significantly, but faces risks from geopolitical tensions impacting supply chains and potentially squeezing margins. OneSource's focus on specialized peptide-based drugs for a high-demand product like semaglutide presents both opportunities and vulnerabilities. The company reported a net loss in the third quarter of fiscal year 2026, a reversal from previous profitability. Adding to financial uncertainty is a pending litigation claim from Prestige Biopharma for ₹12,253.9 million. Furthermore, partner Orbicular Pharmaceutical Technologies has a history of involvement in patent litigations, including common Hatch-Waxman cases for generics, which can lead to costly delays or hinder market entry. Fundamental financial indicators also show strain: promoters have pledged 38.4% of their holdings, debtor days have increased to 105 days, suggesting working capital challenges, and the company has a low interest coverage ratio, negative earnings per share, and low return on equity over the past three years.
CareEdge Ratings maintains a stable outlook for OneSource, expecting revenue growth from the GLP-1 drug market starting in FY27, supported by experienced promoters. The company plans significant capacity expansion, including a $75 million investment driven by GLP-1 demand and potentially a broader $100 million expansion. The Indian pharmaceutical sector overall is projected for steady growth in FY2026, with domestic demand and European exports as key drivers, although the US market faces slower growth due to pricing pressures and regulatory scrutiny. OneSource's future success will depend on navigating the complex path from tentative to final FDA approval, managing its financial risks, and capitalizing on the growing GLP-1 market amidst intensifying generic competition.